Assistant
Ask
Navigate
Command

Merck & Co. Inc. MRK

Merck & Co., Inc. is a global biopharmaceutical company that discovers, develops, manufactures, and markets a broad range of innovative medicines, vaccines, and animal health products. The company's key products include oncology treatments such as Keytruda (pembrolizumab), vaccines including Gardasil, and treatments for infectious diseases and diabetes. Merck is headquartered in Rahway, New Jersey, United States.

Key ratios
FreeCashFlowOnSale TTM 0.19
FreeCashFlowOnSale 2025 0.19
FreeCashFlowOnSale 2024 0.28
FreeCashFlowOnSale 2023 0.15
NetIncomeMargin TTM 0.28
NetIncomeMargin 2025 0.28
NetIncomeMargin 2024 0.27
NetIncomeMargin 2023 0.01
ReturnOnAssets TTM 0.12
ReturnOnAssets 2025 0.12
ReturnOnAssets 2024 0.14
ReturnOnAssets 2023 0.09
ReturnOnEquity TTM 0.37
ReturnOnEquity 2025 0.37
ReturnOnEquity 2024 0.41
ReturnOnEquity 2023 0.01
Recent news
Merck's Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC) 2026-06-22 · Merck
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC) 2026-06-14 · BioSpace
An unhandled error has occurred. Reload 🗙